Stockreport

Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellit...

Adagene Inc. - ADS, each representing 1.25 ordinary shares  (ADAG) 
PDF Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastases Study will be sponsored and conducted by I [Read more]